Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Niagen Bioscience, Inc. (NASDAQ:NAGE) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.42.

Several equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their target price on shares of Niagen Bioscience from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, August 11th.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently modified their holdings of the stock. Financial Consulate Inc. purchased a new position in shares of Niagen Bioscience in the third quarter worth $33,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $144,000. CWM LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $246,000. BSW Wealth Partners purchased a new position in shares of Niagen Bioscience in the third quarter worth $793,000. Finally, Silverberg Bernstein Capital Management LLC purchased a new position in shares of Niagen Bioscience in the third quarter worth $1,169,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Price Performance

Shares of NASDAQ:NAGE opened at $7.51 on Wednesday. Niagen Bioscience has a 1-year low of $3.39 and a 1-year high of $14.69. The company has a market capitalization of $598.95 million, a P/E ratio of 35.76 and a beta of 2.13. The firm’s 50 day simple moving average is $9.05 and its two-hundred day simple moving average is $9.63.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The business had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.